How to Write an Order for Meropenem-Induced Anaphylaxis
If a patient develops anaphylaxis to meropenem, immediately discontinue the drug and administer intramuscular epinephrine 0.3-0.5 mg (1:1000 dilution) in the anterolateral thigh as first-line treatment—do not delay epinephrine administration. 1
Immediate Management Protocol
Primary Treatment
- Epinephrine IM is the only first-line therapy for anaphylaxis 1
- Dose: 0.3-0.5 mg of 1:1000 solution intramuscularly in the anterolateral thigh
- Do not delay administration—early epinephrine correlates with lower morbidity and mortality 1
- May repeat every 5-15 minutes if symptoms persist or recur
Supportive Measures
While epinephrine is being administered:
- Discontinue meropenem infusion immediately 2
- Place patient supine with legs elevated (if tolerated)
- Administer high-flow oxygen
- Establish IV access if not already present
- Begin rapid IV fluid resuscitation with crystalloids or colloids for hypotension 3
Adjunctive Therapies (Secondary Priority)
The evidence for these is very low certainty, but they are commonly used 1:
- H1 antihistamines (e.g., diphenhydramine 25-50 mg IV)
- H2 antihistamines (e.g., ranitidine 50 mg IV or famotidine 20 mg IV)
- Corticosteroids (e.g., methylprednisolone 125 mg IV or dexamethasone 10 mg IV)
Important caveat: Antihistamines and corticosteroids should never replace or delay epinephrine—they are supplemental only 1
Observation and Monitoring
- Keep patient under observation in a setting capable of managing anaphylaxis until symptoms fully resolve 1
- Monitor for biphasic reactions (can occur hours after initial resolution)
- Patients requiring >1 dose of epinephrine are at higher risk for biphasic anaphylaxis 1
- Typical observation period: minimum 4-6 hours for mild reactions, longer for severe reactions
Discharge Planning
Patient Education Requirements 1, 3
- Prescribe epinephrine auto-injector (EpiPen or equivalent) for discharge
- Train patient on self-administration technique
- Provide written instructions on:
- Recognition of anaphylaxis symptoms
- When to use epinephrine auto-injector
- Risk of biphasic reactions
- Strict avoidance of meropenem
Documentation
- Patient should wear medical alert identification (MedicAlert bracelet/necklace) 3, 4
- Document allergy prominently in medical record as "meropenem anaphylaxis"
Alternative Antibiotic Selection
If carbapenem coverage is still needed, consider 5:
- Imipenem-cilastatin may be an option as there is evidence of successful use after meropenem hypersensitivity 5
- However, cross-reactivity between carbapenems exists
- Allergist consultation is strongly recommended before using any alternative beta-lactam 3
Cross-Reactivity Considerations
- Carbapenems have lower cross-reactivity with penicillins than cephalosporins
- If patient has history of penicillin allergy plus meropenem anaphylaxis, avoid all beta-lactams until formal allergy testing 6
- Consider non-beta-lactam alternatives (fluoroquinolones, aminoglycosides, aztreonam) based on infection type
Follow-Up
Mandatory allergist referral for 3:
- Confirmation of IgE-mediated reaction
- Skin testing if indicated
- Evaluation of cross-reactivity risk with other beta-lactams
- Consideration of desensitization if meropenem is absolutely necessary in future
Common Pitfalls to Avoid
- Never delay epinephrine while giving antihistamines or corticosteroids first 1
- Do not use subcutaneous epinephrine—intramuscular route in the thigh is superior
- Do not discharge too early—biphasic reactions can occur up to 72 hours later
- Do not assume all beta-lactams are contraindicated without allergy testing, but exercise extreme caution 6
- Do not restart meropenem even at lower doses—this is not a dose-dependent reaction 4